We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
ExxonMobil
XOM
$650B
| $210M | 0.33% |
1,748,856
-46,529
| -3% | -$5.4M |
|
52
Amgen
AMGN
$209B
| $206M | 0.32% |
629,646
+27,107
| +4% | +$8.6M |
|
53
NextEra Energy
NEE
$184B
| $203M | 0.31% |
2,530,718
-70,009
| -3% | -$5.8M |
|
54
Linde
LIN
$236B
| $201M | 0.31% |
471,886
-25,372
| -5% | -$10.9M |
|
55
Verizon
VZ
$197B
| $200M | 0.31% |
4,906,937
-116,190
| -2% | -$4.71M |
|
56
S&P Global
SPGI
$124B
| $199M | 0.31% |
381,210
+1,515
| +0.4% | +$750K |
|
57
Morgan Stanley
MS
$319B
| $199M | 0.31% |
1,120,122
-19,938
| -2% | -$3.33M |
|
58
Lowe's Companies
LOW
$121B
| $195M | 0.3% |
807,615
+55,675
| +7% | +$13.4M |
|
59
Equinix
EQIX
$99.4B
| $191M | 0.3% |
249,390
-884
| -0.4% | -$693K |
|
60
Bristol-Myers Squibb
BMY
$129B
| $183M | 0.28% |
3,396,965
+216,223
| +7% | +$10.4M |
|
61
Applied Materials
AMAT
$347B
| $183M | 0.28% |
712,005
-8,079
| -1% | -$1.94M |
|
62
Union Pacific
UNP
$174B
| $181M | 0.28% |
784,576
+1,982
| +0.3% | +$452K |
|
63
Adobe
ADBE
$105B
| $181M | 0.28% |
515,981
-16,140
| -3% | -$5.49M |
|
64
Lam Research
LRCX
$316B
| $172M | 0.27% |
1,002,218
+2,935
| +0.3% | +$456K |
|
65
CME Group
CME
$95.4B
| $170M | 0.26% |
623,766
+1,250
| +0.2% | +$340K |
|
66
Berkshire Hathaway Class B
BRK.B
$1.1T
| $170M | 0.26% |
338,501
-9,986
| -3% | -$4.97M |
|
67
PepsiCo
PEP
$196B
| $169M | 0.26% |
1,174,846
-37,042
| -3% | -$5.44M |
|
68
Citigroup
C
$213B
| $166M | 0.26% |
1,422,821
-68,562
| -5% | -$7.12M |
|
69
Trane Technologies
TT
$98.8B
| $161M | 0.25% |
414,107
-11,447
| -3% | -$4.73M |
|
70
McDonald's
MCD
$193B
| $159M | 0.25% |
518,874
-10,006
| -2% | -$3.06M |
|
71
Texas Instruments
TXN
$248B
| $157M | 0.24% |
902,106
-27,693
| -3% | -$4.74M |
|
72
Honeywell
HON
$76.4B
| $156M | 0.24% |
800,839
+11,423
| +1% | +$2.23M |
|
73
Eaton
ETN
$141B
| $154M | 0.24% |
484,648
-6,636
| -1% | -$2.35M |
|
74
Intuit
INTU
$91.1B
| $152M | 0.24% |
229,432
-2,855
| -1% | -$1.89M |
|
75
Walt Disney
DIS
$171B
| $152M | 0.23% |
1,333,652
-31,264
| -2% | -$3.44M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.